FDA approves groundbreaking pancreatic cancer drug from City of Hope research, boosting hope for treatment.
A new analysis shows a 57% rise in accidents involving dangerous chemicals from 2021 to 2025, with injuries and fatalities climbing. More than 650 incidents have occurred since 2020, affecting millions living near facilities, as regulators face pressure to tighten safety rules amid aging infrastructure.
The FDA has approved daraxonrasib, sold as Rasonque, for metastatic pancreatic cancer in patients who have received prior therapy or cannot take combination chemotherapy. Clinical trial data show median survival of 13.2 months versus 6.7 months with chemotherapy. Revolution Medicines has priced a 30‑day supply at about $39,800 and is offering patient assistance.